The replacement of cartilage by bone is the net result of genetic programs that control chondrocyte differentiation, matrix degradation, and bone formation. Disruptions in the rate, timing, or duration of chondrocyte proliferation and differentiation result in shortened, misshapen skeletal elements. In the majority of these skeletal disruptions, vascular invasion of the elements is also perturbed. Our hypothesis is that the processes involved in endochondral ossi®cation are synchronized via the vasculature. The purpose of this study was to examine carefully the events of vascular invasion and matrix degradation in the context of chondrocyte differentiation and bone formation. Here, we have produced a`molecular map' of the initial vascularization of the developing skeleton that provides a framework in which to interpret a wide range of fetal skeletal malformations, disruptions, and dysplasias. q
Results and discussion
The ®rst overt step in endochondral ossi®cation is the aggregation of mesenchymal cells into shapes that resemble the future skeleton. Simultaneously, cells at the periphery of the condensation begin to¯atten and elongate; these cells will form the future perichondrium. Eventually, differentiated chondrocytes reside in the central region of the skeletal element while the proliferative cells lie at the extremities (Fig. 1A) . The most differentiated, hypertrophic, chondrocytes are distinguished from proliferating chondrocytes by their enlarged cytoplasm (Fig. 1A, arrow) . The perichondrium, on the other hand, appears morphologically homogeneous (Fig. 1A) . Gene and protein expression analyses, however, belie this morphological uniformity. For example, at embryonic day 14.0 (e14.0), PECAM-positive endothelial cells are restricted to the perichondrium in the central region of a proximal skeletal element (Fig. 1B) . Two other cell types are also localized to this central region of the perichondrium: osteoclasts and chondroclasts that produce tartrate resistant acid phosphatase (TRAP; Fig. 1C ), and mesenchymal cells that express bone morphogenetic protein 3 (bmp3; Fig. 1D ). The differentiation of the perichondrium is intimately linked to the differentiation of neighboring chondrocytes. This is clearly illustrated by the molecular interactions between the secreted proteins Indian hedgehog (IHH) and BMP3. Ihh is expressed in cells as they exit the proliferative stage and enter the hypertrophic phase of chondrogenesis (Fig. 1D ). An IHH-dependent signal is required for bmp3 expression in the adjoining perichondrium and for the ensuing maturation of the perichondrium into periosteum ( Fig. 1D ; St-Jacques et al., 1999) .
The conversion of a perichondrium into a periosteum is initiated prior to vascularization of the cartilage anlage. By e14.0, cells in the cambial (inner cell) layer of the perichondrium and adjacent to the hypertrophic zone begin to express osteoblast-related genes such as op ( Fig. 1F ; Oldberg et al., 1986) . Op expression, however, is not restricted to the perichondrium; peripheral hypertrophic chondrocytes, which produce collagen type 10 (col10; Fig. 1E ) also express op (Franzen et al., 1989) . Op encodes a glycoprotein involved in integrin-mediated cell adhesion (Smith and Giachelli, 1998; Takahashi et al., 1998) ; its expression in chondrocytes and osteoblasts suggests a role in mediating cell adhesion during chondrogenesis and osteogenesis.
At e14.0 proximal skeletal elements are composed exclusively of avascular cartilage. Vascular endothelial growth www.elsevier.com/locate/modo factor (vegf) is expressed at low levels in a subset of hypertrophic chondrocytes (Fig. 1G) . The VEGF receptor¯k (Fig.  1H ) and a proposed receptor encoded by neuropilin 2 (npn2; Fig. 1I ; Neufeld et al., 1999) are expressed in the perichondrium, suggesting that the perichondrium is a likely target of VEGF signaling.
By e14.0, the matrix metalloproteinases mmp9 (Fig. 1J ) and mt1-mmp (Fig. 1K) , as well as the tissue inhibitor of metalloproteinase, timp3 (Fig. 1L) , are predominantly expressed in the perichondrium, implicating these enzymes in the ensuing conversion of perichondrium to periosteum (Holmbeck et al., 1999; Vu et al., 1998) .
At e15.0, the cartilaginous elements have achieved an hourglass shape ( Fig. 2A) . The perichondrium is noticeably thinner, with the exception of the central region. Here, the perichondrium is thickened and is composed of more PECAM-positive endothelial cells (Fig. 2B ) and TRAPexpressing chondroclasts/osteoclasts (Fig. 2C) than were observed at e14.0. Osteocalcin (oc), which is a molecular marker of osteoblasts differentiation (Lian et al., 1978; Xiao et al., 1999) , is expressed in the thickened perichondrium (Fig. 2D ) while ihh transcripts are detected in mature and early hypertrophic chondrocytes directly beneath the ocpositive perichondrial cells (Fig. 2E ). An IHH-dependent signal is required for the induction of oc in the perichondrium (St-Jacques et al., 1999) , further emphasizing the intimate association between chondrocyte differentiation and the conversion of perichondrium to periosteum. Ihh appears to be gradually down regulated as chondrocytes terminally differentiate (Fig. 2E) ; by the stage of late hypertrophy, chondrocytes no longer express ihh but instead upregulate op (Fig. 2F) . As noted at e14.0, op is also expressed 
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Collagen type 10 (col10) (green) was co-expressed with ihh in early hypertrophic chondrocytes; col10 mRNA was detected in late hypertrophic chondrocytes as well. (F) Osteopontin (op) transcripts (magenta) were localized in the inner layer (cambial layer) of the perichondrium overlying the hypertrophic chondrocyte domain; transcripts were also detected in hypertrophic chondrocytes that bordered the perichondrium. (G) At this stage of skeletal development, vascular endothelial growth factor(vegf) (purple) was weakly expressed in hypertrophic chondrocytes, in the perichondrium and in the surrounding connective tissues. This expression domain was in sharp contrast to that observed only 24 h later (see Fig. 2 ). (H) One VEGF receptor, encoded by¯k-1 (red), was expressed in endothelial cells in the perichondrium as well as in the surrounding soft tissues, while (I) a putative VEGF receptor, encoded by neuropilin2 (npn2) (yellow), was expressed solely in the perichondrium. Transcripts for two matrix-degrading enzymes, (J) matrix metalloproteinase 9 (mmp9) (green) and (K) membrane type 1-matrix metalloproteinase (mt1-mmp) (orange) and transcripts for (L) the tissue inhibitor of matrix metalloproteinase 3 (timp3) (green), were expressed in the perichondrium. In the case of mmp9, this expression is restricted to the perichondrium immediately overlying the hypertrophic chondrocyte domain, in the region where vascular invasion occurs. In the case of mt1-mmp and timp3, transcripts were detected all along the perichondrium. While timp3 transcripts were found in the outer layer of the perichondrium, other perichondrial markers, such as npn2, were found throughout the perichondrium. Scale bars, in the perichondrium, more speci®cally in the cambial layer, and it now partially overlaps with oc, which is also found in the external layer of the perichondrium (Fig. 2F,D) . The expression of a molecule associated with terminal chondrocyte differentiation (e.g. op) in the same cells that express a molecule associated with osteoblast fate (e.g. oc) raises the The ihh domain (red) was separated by the intervening late hypertrophic chondrocytes. Ihh continued to be strongly expressed by mature and early hypertrophic chondrocytes, underlying bmp3 expression (yellow) in the perichondrium. (F) Op (magenta) was expressed in late hypertrophic cartilage and continued to be expressed in the inner layer of the perichondrium. (G) In sharp contrast to its diffuse expression at e14.0, vegf transcripts (purple) had become highly restricted to the late hypertrophic chondrocytes by e15.0. At this stage, the vegf and op domains in the cartilage were comparable, whereas vegf and ihh domains overlapped in only a subset of the cells. (H) Flk (red) and (I) npn2 (yellow) domains were unchanged from e14.0, and continued to be predominantly expressed in the perichondrium. (J) Neuropilin 1 (npn1) (yellow), which was broadly and weakly expressed at e14.0 (data not shown), was primarily identi®ed in late hypertrophic chondrocytes. (K) Mmp9 (green) and (L) mt1-mmp (orange) mRNAs were found in cells in the perichondrium, and at lower levels in some late hypertrophic cells surrounding the future site of vascular invasion. Cells expressing mmp9 in the perichondrium were localized in this particular site. (M) Although not expressed at e14.0, matrix metalloproteinase 13 (mmp13; also known as collagenase 3) transcripts (yellow) were detected at e15.0 in late hypertrophic chondrocytes, coincident with op and vegf. (N) Timp3 (green), which at e14.0 had been expressed solely by cells in the outer layers of the perichondrium, was now detected in early hypertrophic chondrocytes as well. (O) At e14.0, tissue inhibitor of metalloproteinase 2 (timp2) (magenta) was diffusely expressed (data not shown); by e15.0, transcripts were predominantly found in the perichondrium and surrounding connective tissues. Scale bars, (A) 200 mm; (B±O) 200 mm.
possibility that some peripheral chondrocytes may actually undergo transdifferentiation (Franzen et al., 1989) .
By e15.0, the vegf expression domain has changed radically; vegf is now strongly expressed in late hypertrophic chondrocytes and only weakly detected in the surrounding soft tissues (Fig. 2G) . Note, however, that there is still no evidence of vascular invasion in this embryo, while in another embryo from the same litter, the cartilage has become vascularized (Fig. 3) . The majority of the cells expressing the VEGF receptor¯k (Fig. 2H) appear to be endothelial (compare Fig. 2H with Fig. 2B ). The expression domain of the putative VEGF receptor npn2 remains unchanged from e14.0, primarily being restricted to the perichondrium (Fig. 2I) . Another VEGF receptor closely related to Npn2 is Neuropilin 1 (Npn1), a receptor for the collapsin/semaphorin family that mediates neuronal cell guidance (Soker et al., 1998) . Npn1 is expressed in late hypertrophic chondrocytes (Fig. 2J) . These expression showed that vascular invasion occurred at the constriction in the mid-portion of the skeletal element (arrowheads); this invasion by the vasculature divided the hypertrophic zone into two equivalent populations that¯anked a central region of newly formed bone. This site is referred to as the primary ossi®cation center. The area within the box is shown at higher magni®cation in (B±O). (B) PECAM-positive (dark blue) and (C) TRAP-positive (dark purple) cells migrated into the hypertrophic cartilage and were now detected in the primary ossi®cation center. (D) TUNEL activity (green) was restricted to a population of cells that were either peripheral chondrocytes, or cells in the cambial layer of the perichondrium adjacent to the hypertrophic cartilage. No TUNEL-positive cells were detected within the hypertrophic cartilage. (E) Ihh (red) continued to be expressed by mature and early hypertrophic chondrocytes. At earlier stages bmp3 (yellow) was found in the perichondrium overlying the ihh-expressing cells; at this stage of maturation, bmp3 transcripts were also found in the newly formed periosteum. (F) Initially a single domain, col10 (green) was now divided into two regions by the development of the primary ossi®cation center. (G) Vegf (purple) continued to be strongly expressed in late hypertrophic chondrocytes. Cells expressing two of its receptors, encoded by (H)¯k (red) and (I) npn2 (yellow) had migrated into the primary ossi®cation center. The expression of two matrix-degrading enzymes, encoded by (J) mmp9 (green) and (K) mt1-mmp (orange), was strongly up regulated in cells, which had migrated into the primary ossi®cation center. (L) Unlike its cartilage-speci®c expression prior to vascular invasion, mmp13 transcripts (yellow) were detected throughout the primary ossi®cation center after vascular invasion. Mmp13 continued to be expressed by late hypertrophic chondrocytes as well. Although weakly expressed at earlier stages of skeletal development (data not shown), after vascular invasion (M) matrix metalloproteinase 2 (mmp2) transcripts (yellow) were detected in the perichondrium, in resting, proliferating (not shown) and mature chondrocytes and in the surrounding soft tissue. (N) Timp3 (green) and (O) timp2 (magenta) were still expressed in the perichondrium, and at very low levels in the primary ossi®cation center. Timp3 is expressed in early hypertrophic chondrocytes as well. Scale bars, (A) 200 mm; (B±O) 200 mm.
patterns imply that at least two tissues are potentially affected by VEGF signaling: the perichondrium, which expresses¯k, npn2, and another VEGF receptor,¯t (data not shown), and the chondrocytes, which express npn1.
VEGF is bound to the cartilage extracellular matrix, and may be released from this extracellular store by metalloproteinases such as MMP9 (Gerber et al., 1999; Vu et al., 1998) . Mmp9 is strongly expressed in osteoclasts/chondroclasts (Vu et al., 1998) , which are predominantly found in the perichondrium at that stage (Fig. 2K) . Mmp9-expressing cells appear to migrate from the perichondrium into the central region of the hypertrophic cartilage (Blavier and Delaisse Â, 1995) . This event precedes the migration of¯k-positive cells (Fig. 2H) . Given the proposed function of MMP9 in releasing matrix-bound VEGF, the co-expression of these two molecules in the border of the hypertrophic cartilage domain suggests that this is the initial site of VEGF activation. VEGF might then act upon¯k-positive cells immediately adjacent in the perichondrium. The fact that blood vessel invasion will subsequently occur at this precise location further supports this hypothesis (see Fig. 3 ). The membrane-bound metalloproteinase, mt1-mmp, exhibits an expression domain broader than mmp9 in the perichondrium (Fig. 2L) , whereas mmp13, which is directly regulated by CBFA1 (Jime Ânez et al., 1999) , is expressed exclusively in late hypertrophic chondrocytes at this stage ( Fig. 2M ; Kim et al., 1999) . Timp3, which was previously excluded from chondrocytes at e14.0, is now detected in early hypertrophic cells (Fig. 2N) , and timp2 remains predominantly expressed in the perichondrium (Fig. 2O) . Collectively, the concurrent expression of these MMPs indicates that the cartilage matrix is undergoing considerable remodeling immediately preceding vascular invasion.
Vascular invasion occurs rapidly during fetal skeletal development. Whereas the humeri of one e15.0 embryo may not be vascularized (Fig. 2) , the humeri of a littermate may have already undergone invasion (Fig. 3A) . This vascular invasion is visualized by the presence of PECAM- (Fig.  3B ) and TRAP-positive cells (Fig. 3C ) in the center of the hypertrophic zone. Apoptotic chondrocytes cannot be detected in the center of the cartilage element by the TUNEL assay (Fig. 3D ), indicating that chondrocytes may die by physiological mechanisms other than apoptosis (Roach and Clarke, 2000) . The TUNEL-positive cells lining the hypertrophic zone may be pre-osteoblasts, which are derived either from the perichondrium or from transdifferentiating peripheral chondrocytes (Bianco et al., 1998) . TUNEL-positive cells may also be other cell types in the perichondrium such as osteoclasts (Bronckers et al., 1996) .
At the time of vascular invasion, perichondrial cells already differentiate into osteoblasts in the central region of the skeletal element, and continue to express the osteoblast markers bmp3, oc, and op ( Fig. 3E ; data not shown). Cells expressing oc and op start to migrate in the primary ossi®cation center indicating that osteoblasts and endothelial cells migrate concomitantly (data not shown ; Ferguson et al., 1999) . In addition to oc and op, cells in the primary ossi®cation center express many of the same molecules that were once limited to the perichondrium. These include endothelial cells expressing¯k and probably npn2 (Fig.  3H,I ), as well as chondroclasts and osteoclasts expressing mmp9 (Fig. 3J) . Osteoblasts may also express¯k and npn2 (Deckers et al., 2000) . Mt1-mmp-positive cells are also recruited during the initial vascular invasion and might be osteoblast, osteoclasts and/or endothelial cells (Fig. 3K) . Mmp13 is also found in these migrating cells as well as in hypertrophic chondrocytes (Fig. 3L) . Surprisingly, mmp13 was not previously found in the perichondrium suggesting that mmp13 expression is turned on during the migration of endothelial cells and osteoblast precursors in the primary ossi®cation center. Mmp9, mmp13 and mt1-mmp are unlike mmp2 and timp3, which are predominantly expressed in the perichondrium, and at very low levels in the primary ossi®cation center (Fig. 3J±N ). This general increase in the expression of matrix metalloproteinases suggests that their activity serves a vital function in degrading the cartilage matrix and allowing ingression of endothelial and bone cells. The activity of these various matrix metalloproteinases may be limited by the TIMPs, which are strongly expressed in the surrounding perichondrial and connective tissues (Fig. 3N,O) .
Methods

Tissue collection
To ensure precise timing of embryonic stages, mice were mated during a controlled period of 3 h. Forelimbs and hindlimbs were collected on embryonic day 14 (e14.0) (n 5) or day 15 (e15.0) (n 10).
Histological analysis, immunohistochemistry and TUNEL assay
Tissues were ®xed in 4% paraformaldehyde in phosphate buffer saline (PBS), dehydrated in a graded methanol series containing PBS-0.1% Tween, and embedded in paraf®n as previously described (Albrecht et al., 1997) . Five-micrometer sections were placed on TESPA (3-aminopropyltriethoxysilane)-treated slides. Sections were stained with hematoxylin/fast green/Safranin-O. TRAP staining was performed using a leukocyte acid phosphatase detection kit (Sigma, St. Louis, MO). PECAM antibody (Pharmingen) staining was performed as previously described (Vu et al., 1998) . DNA fragmentation in apoptotic cells was identi®ed using the TUNEL method with digoxygenin labeled nucleotides and anti-digoxygenin¯uorescein-conjugated antibody, using the ApoTag kit (Oncor, Gaithersburg, MD).
In situ hybridization
In situ hybridization using antisense 35 SUTP-labeled probes and image analysis were performed as previously described (Albrecht et al., 1997; Ferguson et al., 1999) .
